Pfizer chief executive Albert Bourla said he expects no changes to the company’s most favoured nation pricing arrangements after the US midterm elections, according to Endpoints News reporting on November 3. The comment matters because it is the first senior on the record signal that the negotiated pricing framework survives the election cycle, and it arrived the same day Pfizer raised its 2026 guidance in a story published separately in this edition’s recent coverage.
Federal health officials are working behind the scenes to avoid a jurisdictional clash with states that are setting up clinical AI testing programmes, STAT reported. States license clinicians and regulate the practice of medicine, while the Food and Drug Administration regulates medical devices, and an AI tool that performs clinical work without human supervision sits in both frames at once. The administration has simultaneously sought to reduce regulatory burden on health AI developers and to open Medicare payment paths for the products.
PharmaVoice took stock of Eli Lilly’s rapid pipeline turnover, cataloguing what the company has brought in and what it has dropped across 2026. The piece is analysis rather than a new transaction, and no single deal in it is new to readers of this site, but the cumulative picture is useful: Lilly is reshaping its portfolio at a pace that makes individual licensing headlines a poor guide to its actual strategy.
Two trade roundups on November 3, from Endpoints News and BioPharma Dive, bundled items this site has already published in full, including the Servier sevasemten failure, the uniQure FDA acceptance and May 1, 2027 decision date, the Bright Minds partial hold and the CinRx and Graviton formation of CinRock Pharma. They are noted here for completeness and are not rewritten, in line with cross day dedup.